Swedish Orphan Biovitrum AB (publ)

August 24, 2011 12:54 ET

Resolutions from the Extraordinary General Meeting in Swedish Orphan Biovitrum (Sobi)

STOCKHOLM, SWEDEN--(Marketwire - Aug 24, 2011) -



At the Extraordinary General Meeting (EGM) convened earlier today in Stockholm, the following was resolved in accordance with the proposals by the Board of Directors.

Performance based, long-term share program for the CEO and transfer of own shares The EGM approved the Board of Directors' proposal regarding a performance based, long-term share program for the new CEO Geoffrey McDonough. The share program is based on an own investment in Sobi shares in the market and the allotment requires, among other things, the fulfilment of certain performance based targets related to the development of Sobi's share price.

The EGM also resolved to extend the Board of Directors' authorizations, granted by the Annual General Meeting 2011, to issue and repurchase C-shares to also cover the share program for the CEO. In addition, the EGM approved the Board of Directors' proposal regarding transfer of own shares under the CEO share program in order to secure the company's obligations under the program.

Revised guidelines for remuneration to senior management The EGM further resolved to approve the Board of Directors' proposal on guidelines for remuneration to management.

Full details on each proposal adopted by the EGM can be downloaded from www.sobi.com.


About Swedish Orphan Biovitrum (Sobi) Sobi is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on August 24, 2011 at 6.45 pm CET.




Sobi Press Release August 24, 2011 - pdf format: http://hugin.info/134557/R/1541010/471266.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

[HUG#1541010]

Contact Information

  • For more information, contact:

    Asa Stenqvist
    VP Communications and Investor Relations
    Phone: +46 8 697 21 88